Search Within
Document Type
215-283-8
Applied Filters:
Keyword:'215-283-8'
Showing 1-30 of 41 results for "215-283-8" within Technical Documents
Data Sheet - SAB4200862
11. Jong HK., et al., PLoS Pathog., 8:
e1002933 (2012).
12. BaumLer AJ., et al., Infect Immun., 64:
1862-65 (1996).
13. Zhou D., et al., Science, 283: 2092–95 (1999).
14. Knodler LA.
Data Sheet - A0973
a staining
reaction for detection of the enzyme after
electrophoresis. Anal. Biochem., 273, 278-283
(1999).
JXU/JWM 12/01
Sigma brand products are sold
Data Sheet - M4563
and a staining
reaction for detection of the enzyme after
electrophoresis. Anal. Biochem., 273, 278-283
(1999).
JXU/JWM 12/01
ProductInformation
Sigma brand products are sold through Sigma-Aldrich
Product Information Sheet - E1383
Pharmacopoeia, 28th ed., 208 (1982).
7. Sieber, S.M. et al., Teratology 18, 31, (1978).
8. Stahelin, H., Europ. J. Cancer, 9, 215, (1973).
9. Clark, P.I. and Slevin, M.L., Clinical Pharmacokinetics 12, 223, (
Quality Control Range Sheet- A6041-103 and A6041-203
IFN-γ Control 1 34 - 71 pg/mL IL-8 Control 1 1.2 - 2.5 pg/mL
Control 2 181 - 375 pg/mL Control 2 6.0 - 13 pg/mL
Mid-Infrared-based quantitation of highly modified proteins, labeled peptides and peptidomimetics
’s real MW
per amide (215) and divide by the BSA MW per amide (108).
Re-calculation examples:
BSA-based reading Recalculation Correct concentration
0.500 mg/mL 0.5 * (215/108) = 0.995 mg/mL
1.000
XP725 Antibody Number-Lot Number 071M4826
254 255 256 277 278 279 280
3.5 209 210 211 212 233 234 235 236 257 258 259 260 281 282 283 284
3.6 213 214 215 216 237 238 239 240 261 262 263 264 285 286 287 288
4.1 289
Quality Control Range Sheet- A6602-106 and A6602-206
mL
IFN-γ Control 1 30 – 63 pg/mL IL-10 Control 1 84 – 174 pg/mL
Control 2 136 – 283 pg/mL Control 2
Data Sheet - P1431
262(Pt 1), 803-812
(1989).
14. Meggio, F. et al., FEBS Lett., 215(2), 241-246
(1987).
15. Sacks, D. et al., Biochem. J., 283 (Pt 1), 21-24
(1992).
16. Sacks, D. et al., Biochem. Biophys.
Product Information Sheet - P2277
al., Biochem. J.,262, 803-812 (1989).
18. Meggio, F. et al., FEBS Lett. 215, 241-246 (1987).
19. Sacks, D. et al., Biochem. J., 283-21-24 (1992).
20. Sacks, D. et al., Biochem. Biophys. Res. Comm.,
188
Proteasomes Technical Bulletin
effect on the activity of tripeptidyl
peptidase II.
References:
Geier, E., et al. 1999. Science 283, 978.
Tanaka, K. 1998. J. Biochem. (Tokyo) 123, 195.
Alves-Rodrigues, A., et al. 1998. Trends
Datasheet - F4049
basis of transmission of influenza viruses”.
Imperial College London, Ph.D. dissertation,
p. 283 (2014).
14. Bassi, Christian, “Nuclear PTEN controls DNA
repair and sensitivity to genotoxic stress
Examination of Non-Specifically Bound Proteins and Peptides Following Depletion of Twenty High Abundance Proteins from Human Plasma
Disheveled-associated activator of morphogenesis 46 1
IPI00478493 HP protein 273 8 168 5 374 8
IPI00430808 Hypothetical protein 179 3 217 3 2071 3 215 2 207 3 257 3 483 5
IPI00399007 Hypothetical protein DKFZp 250
Spectroquant Move 100 - Overview of preprogrammed methods
Meth.
No.
Parameter Cat. No. Measuring range Blank Type of
test
Type of
cell
283 Manganese 01846 1.01846.0001 0.05 – 1.80 mg/l Mn RB Test 24 mm
Method list Spectroquant® Colorimeter Move 100
Meth.
No.
Parameter Cat. No. Measuring range Blank Type of
test
Type of
cell
283 Manganese 01846 1.01846.0001 0.05 – 1.80 mg/l Mn RB Test 24 mm
Protocol: GyroMark™ HT Human Insulin Gyros GyrolabTM xP Workstation Assay
100
8 74 76 102
16 37 37 100
32 19 ND
Serum 2 Neat 475 475
2 237 229 97
4 119 116 97
8 59 53 89
User Guide - 3299
Sensitivity = 100 % (12/12)
(95% Confidence Interval 73.5 % - 100 %)
Relative Specificity = 100 % (283/283)
(95% Confidence Interval 98.7 % - 100 %)
PARAINFLUENZA TYPES 1, 2
OxyBlot¿ Protein Oxidation Detection Kit
(II) and L-
ascorbate: conversion of histidine residues to 2-imidazolones. Arch. Biochem. Biophys. 283:20.
19.Heinecke, J.W., et al. (1993) Dityrosine, a specific marker of oxidation, is synthesized
Chrombook (WEB-Version)
1.50482.0001 283
1.50483.0001 283
1.50484.0001 283
1.50487.0001 283
1.50489.0001 283
1.50490.0001 283
1.50491.0001 283
1.50492.0001 283
1.50493.0001 283
1.50494.0001 283
1.50495.0001
Antibody SourceBook, Sixth Edition, DIST version
217602 120 T €283
Anti-CD�9f Mouse mAb (BQ16) FC, FS, IB, IP human 217657 100 µg €31�
Anti-CD5� Mouse mAb (15.2) FC, FS, IB, IP, NT human 217605 100 µg €278
Anti-CD5� Mouse mAb (8.�A6) CIA, ELISA
Cytoskeletal Signaling Antibodies, Reagents and Kits
clone D2D6
06-730 anti-Rho-GDI
05-219 anit-Vav
07-192 Anti-Vav
07-464 anti-Vav3
17-283 Rac
Activation Assay
17-369 Rac2
Activation Assay
14-325 Rac/Cdc42
Assay Reagent
(PAK1, Agarose
Inhibitor Sourcebook 3rd Edition
400051 .......................................................... 215
400076 ........................................................8, 50
400083 .......................................................
XP725 Antibody List Lot 089K4791
PTK2B P NP_004094.3 y n/d n/d
273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1 y y n/d
283 FOXC2 F1054 2303 FOXC2 P NP_005242.1 y y n/d
279 FKHR (FOXO1a) F6928 2308 FOXO1 M NP_002006.2 y n
XP725 Antibody List Lot 129K4831
PTK2B P NP_004094.3 y n/d n/d
273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1 y y n/d
283 FOXC2 F1054 2303 FOXC2 P NP_005242.1 y y n/d
279 FKHR (FOXO1a) F6928 2308 FOXO1 M NP_002006.2 y n
XP725 Antibody List Lot 129K4830
PTK2B P NP_004094.3 y n/d n/d
273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1 y y n/d
283 FOXC2 F1054 2303 FOXC2 P NP_005242.1 y y n/d
279 FKHR (FOXO1a) F6928 2308 FOXO1 M NP_002006.2 y n
Perfection in every dimension - Inorganic Reagents catalog
form 107150 283
Paraffin 46 – 48, in block form 107151 283
Paraffin 51 – 53, in pastille form Ph Eur, BP, NF 107157 283
Paraffin 52 – 54, in pastille form Ph Eur, BP, NF 107300
MAPK: Antibodies, Proteins, Kits, siRNA and Reagents
100 µg 04-282
Anti-phospho-EGFR (Thr669) 100 µg 04-281
Anti-phospho-EGFR (Tyr845) 100 µg 04-283
Anti-phospho-EGFR (Tyr1045) 100 µg 04-284
Anti-phospho-EGFR (Ser1047) 100 µg 04-280
Anti-phospho-EGFR
List of Antibodies
FOXO3a) F2178 P y y n/d
281 FKHRL1 (FOXO3a) F1304 M y n/d n/d
282 FLIPγ/δ, C-Terminal F9925 P y y n/d
283 FOXC2 F1054 P y y n/d
284 FOXP2 F6304 P y y y
285 FANCD2 F0305 P y y y
286 FXR2 F1554
XP725 Worksheet for Lot Number 071M4826
7 b Catenin pSer33pSer37 C4231
280 2 2 5 8 bCatenin pSer33pSer37 C4231
281 2 2 6 1 phospho-b-Catenin pSer45 C5615
282 2 2 6 2 phospho-b-Catenin pSer45 C5615
283 2 2 6 3 bCatenin pSer33 C2363
284 2 2 6 4
XP725 Antibody List
y n/d n/d
282 FLIPγ/δ, C-Terminal F9925 12633, 8837 Cflar,CFLAR NP_997536.1,NP_003870.3 P y y n/d
283 FOXC2 F1054 14234, 2303 Foxc2,FOXC2 NP_038547.2,NP_005242.1 P y y n/d
284 FOXP2 F6304 93986, 114142
Page 1 of 2